Search - tctmd.com

Displaying 21 - 40 of 107

Sort: Relevancy | Date

News Conference News ACC 2024

Heavy Drinking May Contribute to CHD Risk in Young Women

L.A. McKeown

April 02, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Todd Neale

March 09, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Conference News ACC 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

Caitlin E. Cox

March 05, 2023

Presentation ACC 2023

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Presenter: Neha J. Pagidipati

March 05, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Shelley Wood

May 16, 2021

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

Advertisement

Heavy Drinking May Contribute to CHD Risk in Young Women

What’s Going to Be Hot at ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Managing AF Patients Undergoing PCI—Some Lingering Questions

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content